Medicines Citation, commencement and extent 1 1 These Regulations may be cited as the Medicines (Products for Human Use) (Fees) (Amendment) Regulations 2023. 2 These Regulations come into force on 1st April 2023. 3 These Regulations extend to England and Wales, Scotland and Northern Ireland. Amendment of the Medicines (Products for Human Use) (Fees) Regulations 2016 2 The Medicines (Products for Human Use) (Fees) Regulations 2016 are amended in accordance with regulations 3 to 26. Amendment of regulation 4 3 In regulation 4 (fee for scientific advice: application for, or variation to, EU marketing authorisation)— a in paragraph (a), for “£2,201” substitute “£2,421” , b in paragraph (b), for “£2,763” substitute “£3,039” , c in paragraph (c), for “£3,061” substitute “£3,367” , d in paragraph (d), for “£3,624” substitute “£3,986” , and e in paragraph (e), for “£4,487” substitute “£4,936” . Amendment of regulation 5 4 In regulation 5(1) (fee for scientific advice: classification of a medicinal product)— a in sub-paragraph (a), for “£2,763” substitute “£3,039” , and b in sub-paragraph (b), for “£3,624” substitute “£3,986” . Amendment of regulation 6 5 In regulation 6 (fee for advertising advice), for “£2,201” substitute “£2,421” . Amendment of regulation 7 6 In regulation 7(1) (fee for pharmacovigilance advice)— a in sub-paragraph (a), for “£3,624” substitute “£3,986” , and b in sub-paragraph (b), for “£3,061” substitute “£3,367” . Amendment of regulation 8 7 In regulation 8 (fee for advice on labelling or leaflets), for “£2,201” substitute “£2,421” . Amendment of regulation 9 8 In regulation 9 (fee for regulatory advice), for “£2,763” substitute “£3,039” . Amendment of regulation 10 9 In regulation 10(1) (fee for advice for other purposes), for “£4,451” substitute “£4,896” . Amendment of regulation 12 10 In regulation 12(1) (fees for applications for authorisations, registrations, licences or certificates etc.), after “a broker’s registration”, insert “, an application under the Early Access to Medicines Scheme” . Amendment of regulation 14 11 In regulation 14 (fee for applications for additional copy certificates), for “£68” substitute “£75” . Amendment of regulation 15 12 In regulation 15 (fees for applications for certificates and copy certificates by exporters of medicinal products)— a in paragraph (1)(a), for “£152” substitute “£167” , b in paragraph (1)(b), for “£68” substitute “£75” , and c in paragraph (3), for “£34” substitute “£37” . Amendment of regulation 19A 13 In regulation 19A (fees for certification of plasma master files)— a in paragraph (1), for “£8,309” substitute “£9,140” , b in paragraph (2)(a), for “£277” substitute “£344” , and c in paragraph (2)(b), for “£734” substitute “£1,308” . Amendment of regulation 19B 14 In regulation 19B (fee for certification of vaccine antigen master files), for “£8,309” substitute “£9,140” . Amendment of regulation 19C 15 In regulation 19C (fees for assessment of post-authorisation safety studies)— a in paragraph (2)— i in sub-paragraph (a), for “£734” substitute “£1,308” , ii in sub-paragraph (b), for “£8,309” substitute “£9,140” , iii in sub-paragraph (c), for “£734” substitute “£1,308” , and b in paragraph (3)— i in sub-paragraph (a), for “£734” substitute “£1,308” , ii in sub-paragraph (b), for “£8,309” substitute “£9,140” , and iii in sub-paragraph (c), for “£734” substitute “£1,308” . Amendment of regulation 19E 16 In regulation 19E(2) (fee for assessment of periodic safety update reports)— a in sub-paragraph (a), for “£890” substitute “£979” , and b in sub-paragraph (b), for “£445” substitute “£490” . New regulation 19EA 17 After regulation 19E, insert— Fee for assessment of clinical trial annual safety reports 19EA The fee payable by a sponsor who submits an annual safety report to the licensing authority under regulation 35(1)(b) of the Clinical Trials Regulations is £248. . Amendment of regulation 21 18 In regulation 21(1) (fees for notification of changes and reports for broker’s registrations), for “£257” substitute “£283” . Amendment of regulation 22 19 In regulation 22(1) (fees for notification of changes and compliance reports for active substance registrations), for “£257” substitute “£283” . Amendment of regulation 27 20 In regulation 27 (fees for renewals of certain manufacturer’s licences)— a in paragraph (1), for “£178” substitute “£196” , and b in paragraph (3), for “£295” substitute “£325” . Amendment of regulation 41 21 In regulation 41 (fees for applications for membership and certificates)— a in paragraph (1), for “£117” substitute “£129” , and b in paragraph (2), for “£62” substitute “£68” . Amendment of regulation 42 22 In regulation 42(1) (fee for a review upon oral representations or a person appointed hearing), for “£10,000” substitute “£11,000” . Amendment of Schedule 1 23 In Schedule 1 (general interpretation provisions), in paragraph 1 (interpretation), in the appropriate place insert— “ Early Access to Medicines Scheme ” has the meaning given in regulation 8(1) of the Human Medicines Regulations; . Amendment of Schedule 2 24 1 Schedule 2 (capital fees for applications for, and variations to, marketing authorisations, licences, registrations and certificates) is amended as follows. 2 In paragraph 1 (interpretation)— a after the definition of “active ingredient from a new source”, insert— “ EAMS scientific opinion ” has the meaning given in regulation 8(1) of the Human Medicines Regulations; , and b after the definition of “Phase IV trial”, insert— “ Promising Innovative Medicines designation ” means a designation issued by the licensing authority under the Early Access to Medicines Scheme in accordance with regulation 167C(2)(a) of the Human Medicines Regulations; . 3 In paragraph 24(5) (marketing authorisations), in the second column (fee payable) of the table (fees for marketing authorisation applications)— a in item 1 (major application)— i in entry (a), for “£29,732” substitute “£32,705” , ii in entries (b) to (d), for “£62,421” substitute “£68,663” , iii in entry (e), for “£18,437” substitute “£20,281” , iv in entry (f), for “£62,421” substitute “£68,663” , v in entry (g), for “£18,437” substitute “£20,281” , vi in entry (h), for “£92,753” substitute “£102,028” , b in item 2 (complex application)— i in entries (a) to (c), for “£17,330” substitute “£19,063” , ii in entry (d), for “£10,443” substitute “£11,487” , iii in entry (e), for “£17,330” substitute “£19,063” , iv in entry (f), for “£10,443” substitute “£11,487” , v in entry (g), for “£25,643” substitute “£28,207” , c in item 3 (standard application)— i in entries (a) to (c), for “£6,350” substitute “£6,985” , ii in entry (d), for “£5,783” substitute “£6,361” , iii in entry (e), for “£6,350” substitute “£6,985” , iv in entry (f), for “£5,783” substitute “£6,361” , v in entry (g), for “£9,402” substitute “£10,342” , d in item 4 (simple application), in entries (a) to (f), for “£2,564” substitute “£2,820” , e in item 5 (parallel import licence applications)— i in entry (a), for “£1,792” substitute “£1,971” , ii in entry (b), for “£6,663” substitute “£8,722” , iii in entry (c), for “£18,180” substitute “£19,998” , and f in item 6 (change of ownership application), for “£442” substitute “£486” . 4 In paragraph 25(1) (fees where application includes reclassification)— a in sub-paragraph (a), for “£11,992” substitute “£33,003” , and b in sub-paragraph (b), for “£8,162” substitute “£8,978” . 5 In paragraph 27 (joint development)— a in sub-paragraph (2)— i in paragraph (a)(i), for “£17,330” substitute “£19,063” , ii in paragraph (b)(i), for “£6,350” substitute “£6,985” , iii in paragraph (c)(i), for “£17,330” substitute “£19,063” , iv in paragraph (d)(i), for “£6,350” substitute “£6,985” , and b in sub-paragraph (3)(a)(i), for “£6,350” substitute “£6,985” . 6 In paragraph 28 (application for multiple authorisations)— a in sub-paragraph (2)— i in paragraph (a)(i), for “£17,330” substitute “£19,063” , ii in paragraphs (b)(i) and (c)(i), for “£6,350” substitute “£6,985” , b in sub-paragraph (3), in paragraphs (b)(i) and (c)(i), for “£6,350” substitute “£6,985” , and c in sub-paragraph (4)(b), for “£734” substitute “£1,308” . 7 In paragraph 28A (application by pre-assessment of modules)— a in sub-paragraphs (1)(a) to (c), for each “£23,188.25” substitute “£25,507” , and b in sub-paragraphs (2)(a) to (c), for each “£4,332.50” substitute “£4,766” . 8 In paragraph 30(1) (manufacturer’s licences and authorisations)— a in paragraph (a), for “£183” substitute “£201” , b in paragraph (b), for “£344” substitute “£378” , and c in paragraph (c), for “£3,143” substitute “£3,457” . 9 In paragraph 31 (wholesale dealer’s licences)— a in sub-paragraph (1), for “£1,803” substitute “£1,983” , b in sub-paragraph (2), for “£902” substitute “£992” , and c in sub-paragraph (5), for “£399” substitute “£439” . 10 In paragraph 32 (broker’s registrations)— a in sub-paragraph (1), for “£1,803” substitute “£1,983” , and b in sub-paragraph (2), for “£399” substitute “£439” . 11 In paragraph 33 (active substance registrations)— a in sub-paragraph (1)— i in paragraph (a), for “£3,143” substitute “£3,457” , ii in paragraph (b), for “£1,803” substitute “£1,983” , and b in sub-paragraph (2), for “£399” substitute “£439” . 12 In paragraph 34 (clinical trial authorisations)— a in sub-paragraph (a), for “£3,060” substitute “£3,366” , and b in sub-paragraph (b), for “£225” substitute “£248” . 13 In paragraph 35(1) (traditional herbal registrations), in the second column (fee payable) of the table (fee for application for traditional herbal registration), in entry 5 (change of ownership application), for “£442” substitute “£486” . 14 After paragraph 35, insert— Early Access to Medicines Scheme fees 35A The fee payable under regulation 12(1)(a) in connection with an application submitted under the Early Access to Medicines Scheme of a kind described in column 1 of the following table is the fee specified in the corresponding entry in column 2 of that table. Fees for Early Access to Medicines Scheme applications Column 1 Column 2 Kind of Application Fee payable 1. Promising Innovative Medicine (PIM) designation £3,986 2. EAMS scientific opinion for new medicinal products £25,643 3. Renewal of an EAMS scientific opinion for new chemical or biological medicinal products £12,821 4. EAMS scientific opinion for new indications £8,309 5. Renewal of an EAMS scientific opinion for new indications £4,154 15 In paragraph 38 (marketing authorisations)— a in the second column (fee payable) of Table 1 (fees for applications for variations of marketing authorisations falling within the scope of Chapter II of Commission Regulation (EC) No 1234/2008 )— i in entries 1(a) and 1(b), for “£277” substitute “£344” , ii in entry 1(c), for “£2,493” substitute “£2,742” , iii in entry 1(d), for “£7,693” substitute “£8,462, iv in entry 2(a), for “£277” substitute “£344” , v in entry 2(b), for “£496” substitute “£1,255” , vi in entry 2(c), for “£2,703” substitute “£2,973” , vii in entry 2(d), for “£7,883” substitute “£8,671” , b in the second column (fee payable) in Table 2 (fees for applications for variations of marketing authorisations falling within the scope of Chapter IIa of Commission Regulation (EC) No 1234/2008 and of marketing authorisations in force in Great Britain)— i in entry 1, for “£277” substitute “£344” , ii in entry 2, for “£734” substitute “£1,308” , iii in entry 3, for “£8,309” substitute “£9,140” , iv in entry 4, for “£25,643” substitute “£33,003” , v in entry 5, for “£622” substitute “£684” , vi in entry 6, for “£1,652” substitute “£1,817” , vii in entry 7, for “£9,010” substitute “£9,911” , viii in entry 8, for “£26,276” substitute “£28,904” , and c in the second column (fee payable) in Table 3 (fees for reclassification variation applications)— i in entry (a), for “£11,992” substitute “£33,003” , ii in entry (b), for “£8,162” substitute “£8,978” . 16 In paragraph 40(1) (reclassification of marketing authorisations), for “£734” substitute “£1,308” . 17 In paragraph 42(1) (variation of parallel import licence)— a in paragraph (a), for “£11,992” substitute “£33,003” , b in paragraph (b), for “£8,162” substitute “£8,978” , and c in paragraph (c), for “£357” substitute “£393” . 18 In paragraph 43 (manufacturer’s authorisations and licences)— a in sub-paragraph (a), for “£257” substitute “£283” , and b in sub-paragraph (b), for “£514” substitute “£565” . 19 In paragraph 44 (variation of manufacturer’s authorisations and licences), for “£257” substitute “£283” . 20 In paragraph 45 (wholesale dealer’s licences), for “£486” substitute “£535” . 21 In paragraph 46 (variation of wholesale dealer’s licence), for “£257” substitute “£283” . 22 In paragraph 47 (variation of a broker’s registration), for “£257” substitute “£283” . 23 In paragraph 48 (variation of an active substance registration), for “£257” substitute “£283” . 24 In paragraph 49(1) (clinical trial authorisations) for “£225” substitute “£248” . 25 In paragraph 53(a)(ii) (multiple reclassification variation applications), for “£734” substitute “£1,308” . 26 In paragraph 54 (a set of changes)— a in sub-paragraph (1)— i in paragraph (a), for “£518” substitute “£570” , ii in paragraph (b), for “£328” substitute “£361” , and b in sub-paragraph (2), for “£186” substitute “£205” . 27 In paragraph 56 (renewal of a marketing authorisation)— a in sub-paragraphs (a) and (b), for “£747” substitute “£822” , and b in sub-paragraph (c), for “£9,682” substitute “£10,650” . 28 In paragraph 57(2) (renewal of multiple marketing authorisations)— a in sub-paragraphs (a)(i) and (a)(ii), for “£747” substitute “£822” , b in sub-paragraph (b)(i), for “£9,682” substitute “£10,650” , and c in sub-paragraph (b)(ii), for “£747” substitute “£822” . 29 In paragraph 57A (capital fee for conducting a major safety review)— a in sub-paragraph (a), for “£51,286” substitute “£56,415” , b in sub-paragraph (b), for “£59,595” substitute “£65,555” , c in sub-paragraph (c), for “£67,904” substitute “£74,694” , and d in sub-paragraph (d), for “£76,213” substitute “£83,834” . 30 In paragraph 57B(4) — a in the second column (fee payable where the licensing authority carries out a full assessment) of the table (fees for testing of samples)— i in entry 1(a), for “£180” substitute “£198” , ii in entry 1(b), for “£215” substitute “£237” , iii in entry 1(c), for “£230” substitute “£253” , iv in entry 2, for “£1,660” substitute “£1,826” , v in entry 3, for “£1,910” substitute “£2,101” , vi in entry 4, for “£2,340” substitute “£2,574” , vii in entry 5, for “£3,690” substitute “£4,059” , viii in entry 6, for “£6,410” substitute “£7,051” , ix in entry 7, for “£10,350” substitute “£11,385” , and b in the third column (fee payable where the licensing authority carries out a paper-based assessment) of the table— i in entries 1(a), (b) and (c), for “£90” substitute “£99” , ii in entries 2 and 3, for “£305” substitute “£367” , iii in entry 4, for “£305” substitute “£992” , iv in entry 5, for “£677” substitute “£992” , v in entries 6 and 7, for “£677” substitute “£1,849” . Amendment of Schedule 3 25 1 Schedule 3 (fees for inspections) is amended as follows. 2 In paragraph 2(1) (fees: general)— a in paragraph (a), for “£2,655” substitute “£3,651” , and b in paragraph (b), for “£1,328” substitute “£1,825” . 3 In paragraph 5 (wholesale dealer’s licence: general)— a in sub-paragraphs (a) and (b), for “£1,936” substitute “£2,662” , and b in sub-paragraph (b), for “£968” substitute “£1,331” . 4 In paragraph 6(2) (wholesale dealer’s licence: traditional herbal medicinal products)— a in paragraph (a), for “£744” substitute “£1,023” , and b in paragraphs (b) and (c), for “£1,367” substitute “£1,880” . 5 In paragraph 7(3) (wholesale dealer’s licences: inspection of short duration), for “£968”, substitute “£1,331” . 6 In paragraph 8 (broker’s registrations)— a in sub-paragraph (1)— i in paragraphs (a) and (b), for “£1,936” substitute “£2,662” , ii in paragraph (b), for “£968” substitute “£1,331” , and b in sub-paragraph (3), for “£582” substitute “£640” . 7 In paragraph 9 (active substance registrations)— a in sub-paragraph (1)(a)— i in sub-paragraphs (i) and (ii), for “£2,655” substitute “£3,651” , ii in sub-paragraph (ii), for “£1,328” substitute “£1,825” , b in sub-paragraph (1)(b)— i in sub-paragraphs (i) and (ii), for “£1,936” substitute “£2,662” , ii in sub- paragraph (ii), for “£968” substitute “£1,331” , and c in sub-paragraph (3)— i in paragraph (a), for “£792” substitute “£871” , ii in paragraph (b), for “£582” substitute “£640” . 8 In paragraph 10 (office-based inspections)— a in sub-paragraph (a), for “£1,863” substitute “£2,562” , and b in sub-paragraph (b), for “£1,354” substitute “£1,862” . Amendment of Schedule 4 26 1 Schedule 4 (periodic fees for licences) is amended as follows. 2 In paragraph 5 (marketing authorisations), in column 2 (fee payable) of the table (periodic fees for holding a marketing authorisation)— a in entry 1, for “£9,710” substitute “£10,681” , b in entry 2, for “£307” substitute “£338” , c in entry 3(a), for “£9,710” substitute “£10,681” , d in entry 3(b)(i), for “£2,428” substitute “£2,671” , e in entry 3(b)(ii), for “£1,211” substitute “£1,332” , f in entries 3(b)(iii), (c) and (d), for “£307” substitute “£338” , and g in entries 3(e) to (h), for “£76” substitute “£84” . 3 In paragraph 6 (marketing authorisation: where Part 2 of the Act applies), for “£307” substitute “£338” . 4 In paragraph 7 (marketing authorisation: derivatives)— a in sub-paragraph (a), for “£9,710” substitute “£10,681” , and b in sub-paragraph (b), for “£6,554” substitute “£7,209” . 5 In paragraph 11(1) and (2) (manufacturer’s licences or manufacturing authorisations), for “£468” substitute “£515” . 6 In paragraph 12 (wholesale dealer’s licences)— a in sub-paragraph (1), for “£288” substitute “£317” , and b in sub-paragraph (2), for “£172” substitute “£189” . 7 For paragraph 15(1), substitute— 1 The additional amount referred to in paragraphs 11(3) and 14 in relation to any fee period is— a the fee specified in the entry in column 2 of Table 1 (additional periodic fee in connection with notices for imported special medicinal products) corresponding to the estimated number of special import notices for that fee period specified in column 1, and b the fee specified in the entry in column 2 of Table 2 (additional periodic fee in connection with the number of different special medicinal products imported) corresponding to the estimated number of different special medicinal products imported for that fee period specified in column 1. Table 1 Additional periodic fee in connection with notices for imported special medicinal products Column 1 Column 2 Number of special import notices Additional amount 1 to 20 £70 21 to 100 £350 101 to 1,000 £2,400 1,001 to 5,000 £12,000 5,001 to 20,000 £30,000 20,001 to 50,000 £60,000 50,001 to 100,000 £120,000 100,001 or more £200,000 Table 2 Additional periodic fee in connection with the number of different special medicinal products notified for import Column 1 Column 2 Number of different special medicinal products notified for import Additional amount 1 to 5 £100 6 to 10 £200 11 to 20 £400 21 to 50 £1,000 51 to 100 £2,000 101 to 200 £4,000 For each additional 100 special medicinal products notified for import above 200 £2,000 8 After paragraph 15(2), insert— 3 For the purposes of this paragraph, the estimated number of different special medicinal products notified for import for any fee period shall be the number notified in writing to the licence holder by the licensing authority before the start of that fee period as the number of such notices which the authority estimate will be given by the holder during the fee period. . 9 In paragraph 16 (traditional herbal registrations), for “£76” substitute “£84” . Signed by authority of the Secretary of State for Health and Social Care Will Quince Minister of State, Department of Health and Social Care 9th March 2023 Sealed with the Official Seal of the Department of Health in Northern Ireland 8th March 2023 Cathy Harrison A senior officer of the Department of Health in Northern Ireland